How does letrozole induce ovulation and improve fertility in women with polycystic ovary syndrome (PCOS)?

Letrozole in PCOS: Mechanism and Clinical Role

Letrozole is an aromatase inhibitor that induces ovulation in women with PCOS by temporarily blocking estrogen synthesis, which triggers increased FSH release from the pituitary, leading to follicular development and ovulation—and it has emerged as a first-line treatment for anovulatory infertility in PCOS with superior live birth rates compared to clomiphene citrate. 1

Mechanism of Action

Letrozole works through a fundamentally different pathway than traditional ovulation induction agents:

• Blocks aromatase enzyme: Prevents conversion of androgens to estrogen in peripheral tissues and ovarian follicles 2
• Reduces circulating estrogen: This temporary estrogen suppression removes negative feedback on the hypothalamic-pituitary axis
• Increases FSH secretion: The pituitary responds to low estrogen by releasing more FSH, stimulating follicular development
• Preserves estrogen receptors: Unlike clomiphene citrate, letrozole does not deplete estrogen receptors, so normal negative feedback resumes once the drug is cleared (short half-life) 2
• Results in monofollicular ovulation: Because estrogen receptors in the brain remain functional, normal feedback mechanisms typically produce single dominant follicle development rather than multiple follicles 1

Clinical Efficacy

The evidence strongly supports letrozole's effectiveness:

Live birth rates: A large NIH-sponsored multicenter randomized trial (n=750) demonstrated marked superiority of letrozole over clomiphene for live birth rates in anovulatory PCOS women, with comparable safety profiles 1. This finding has fundamentally shifted treatment paradigms.

Ovulation rates: Letrozole achieves significantly higher follicular response rates, particularly with extended protocols. The 10-day regimen shows 85% follicular response versus 52.5% with standard 5-day protocols in the first cycle 3

Endometrial effects: A critical advantage is that letrozole significantly improves endometrial thickness (9.16 ± 1.36 mm) compared to clomiphene (4.46 ± 1.71 mm), because it lacks antiestrogenic effects on the endometrium 4. This translates to better implantation potential.

Pregnancy rates: Studies show higher pregnancy rates with letrozole compared to clomiphene, with lower multiple pregnancy risk due to more frequent monofollicular ovulation 4

Clinical Application Algorithm

First-line use: The Endocrine Society recommends clomiphene citrate or comparable estrogen modulators such as letrozole as first-line treatment for anovulatory infertility in PCOS 1. Given the 2013 NIH trial data showing letrozole superiority, it should be considered the preferred first-line agent.

Dosing protocols:

• Standard: 2.5 mg daily for 5 days starting cycle day 3-5
• Extended protocol: 2.5 mg daily for 10 days—this significantly improves follicular response (85% vs 52.5%) and reduces need for dose escalation 3
• Dose escalation: Can increase to 5 mg or 7.5 mg daily in subsequent cycles if no response

Sequential therapy: When combined with gonadotropins, letrozole increases ovulation rates (OR 1.74) and endometrial thickness while reducing gonadotropin dose requirements 5. This is particularly useful in clomiphene-resistant cases.

Monitoring: Transvaginal ultrasound folliculometry to assess follicle number, size (trigger at ≥18 mm), and endometrial thickness 4

Important Safety Considerations

Teratogenicity concerns: Early concerns about letrozole teratogenicity have been largely dispelled. The 2013 guideline notes that the large NIH trial and other publications are reassuring regarding safety 1. However, the FDA label indicates animal studies showed fetal toxicity and teratogenic effects 6.

Practical safety measures:

• Pregnancy testing before initiating treatment 6
• Effective contraception during treatment and for 3 weeks after last dose 6
• Avoid breastfeeding during treatment and for 3 weeks after 6
• Monitor for fatigue and dizziness which may affect driving 6
• Consider bone mineral density monitoring with prolonged use 6

Fertility effects: Animal studies suggest potential impairment of fertility in both males and females, though this is based on preclinical data 6

Advantages Over Alternatives

Compared to clomiphene citrate:

• No estrogen receptor depletion or antiestrogenic effects
• Better endometrial thickness
• No adverse effects on cervical mucus
• Shorter half-life allowing better cycle control
• Lower multiple pregnancy rates (monofollicular ovulation)
• Superior live birth rates 1, 2

Compared to metformin:

• Metformin shows limited efficacy for improving reproductive outcomes in PCOS, with no improvement in live birth rates whether used alone or with clomiphene 1
• Letrozole's success underscores estrogen modulators as superior first-line agents compared to insulin sensitizers 1

Common Pitfalls to Avoid

1. Inadequate dosing duration: Consider extended 10-day protocols rather than standard 5-day regimens for better response rates 3

2. Premature abandonment: Allow up to 3 cycles before declaring treatment failure 3

3. Ignoring endometrial assessment: Unlike clomiphene, letrozole improves rather than impairs endometrial development—this is a key advantage that should be monitored 4

4. Unnecessary gonadotropin escalation: Letrozole alone may be sufficient; reserve combination therapy for resistant cases 5

The evidence clearly positions letrozole as a highly effective, well-tolerated first-line agent for ovulation induction in PCOS, with mechanisms that address both ovulatory dysfunction and endometrial receptivity while minimizing multiple pregnancy risk.